Glagov
Prof Steve Nicholls: Is there a link between the benefit of evolocumab observed in GLAGOV & FOURIER?
read more »PCSK9 inhibitors: cardiovascular benefit vs. diabetes risk
Two published Mendelian randomization studies have provided insights into potential long-term effects of PCSK9 inhibition. The studies follow hot on the heels of the GLAGOV study, which showed that treatment with evolocumab on top of statin induced atherosclerosis regression compared with statin alone (1). According…
read more »Anthony Wierzbicki, Guy’s & St Thomas’ Hospitals, London discusses the implications of key trials at AHA 2016
Anthony Wierzbicki, Guy’s & St Thomas’ Hospitals, London discusses the implications of key trials at AHA 2016 GLAGOV ORION
read more »GLAGOV in context: A view from the PCSK9 Forum Editors
The results of GLAGOV, reported at AHA Scientific Sessions and now published in JAMA (1) are of keen interest to the clinical community, with the major outcomes study FOURIER with evolocumab expected early in 2017. PCSK9 Forum Editors Professor Henry Ginsberg and Professor John Chapman…
read more »GLAGOV results: Greater plaque regression with evolocumab
Results of the GLAGOV study (Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound) showed that treatment with the PCSK9 inhibitor evolocumab on top of statin led to further lowering of low-density lipoprotein cholesterol (LDL-C) beyond current guideline recommendations, and…
read more »Current status of IVUS studies of plaque burden: what next with GLAGOV?
Over the last decade, the use of serial intravascular ultrasound (IVUS) imaging has been critical for defining the relationship between achieved LDL cholesterol levels and atherosclerotic plaque burden. In this overview, Professor Steve Nicholls (South Australian Health and Medical Research Institute, Adelaide, Australia) discusses the…
read more »